Guwahati: ASSAM’s health authority and those who qualified for Covid-19 vaccination are currently at the mercy of uncertain vaccine supply to the state by the central government.
The Ministry of Health has been forced to summarize three lakh vaccination targets, which resulted in thousands of people who return from the vaccination center without getting the specified dose.
In addition, there is no certainty when the country will get the next supply.
NHM officials said the vaccine supply from the center was not “erratic”, but “not uniform, who placed the brakes at the speed of vaccination.
They added that the supply of the Covid-19 vaccine dropped after the enhanced immunization drive had entered the third day.
The drive starts from 21 June with the target vaccination of three lakh every day.
Initially the drive was successful as 9.75 people lakh received a vaccination shot at 2,425 vaccine centers in the first three days.
On Friday, only 1,545 CVCs were operated with 1.63 lakh people who received vaccination.
On On Wednesday, the total number of vaccinated people was 70.22,282, while more than 1.72 lakh was inoculated on Thursday.
“We want to vaccinate the maximum number of people within the minimum time.
But the critics here are the availability of vaccines, “said NHM Director Lakshhman.” We are worried that a large number of people must return without vaccination, which is unfortunate, “he said,” we have shown us.
“Capacity and within a constant touch with government officials stating that this is how we become inoculation and vaccination capacity per day.
The Union Government knows our capacity and allocate vaccines according to their availability.” He added that after the authorities learned about the availability of allocations The proposed vaccine, they told the district and then distributed vaccines between their requirements, Covid capacity and situation.
“There was a short supply of only Bharat Biotech’s Covaxin which forced the suspension of the first dose of Covaxin on June 4, but then the availability of covishield by the Indian Serum Institute was also a problem, he said.